hotspot -WSS

hotspot

author：explore 2025-09-10 02:23:04 - browse：41196

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： STAT wants to know your pick for a great summer read or listen

knowledge

WSS

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

In 'major milestone,' FDA approves first cell therapy for solid tumors

FDA warns medical device makers about rise in fabricated data

New CMS data security rules will hurt Medicare, Medicaid research

Lupron, used to halt puberty in children, may cause lasting health problems

Secretariat’s lessons for human medicine

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Skip the lead apron during X

The high cost of giving birth even with insurance

STAT wants to know your pick for a great summer read or listen

ChatGPT in medicine: STAT answers readers' burning questions

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Trump demands the U.S. pay no more for drugs than other countries … again

Drug cartel violence flares in western Mexico after vigilante leader's killing

How one medical school became remarkably diverse

What affirmative action's end means to a medical student

focus

Surprise medical billing ban raises prices elsewhere

Prescription digital therapeutics are key to pharma’s future

Vertex cell therapy lets patients with type 1 diabetes stop insulin

'Screen and refer' systems are hurting patients

'Screen and refer' systems are hurting patients

Secretariat’s lessons for human medicine

knowledge

leisure time

explore

hotspot